Bannerbild German Brest Group

October 2018: Long-term survival analysis of GeparSixto trial

05.11.2018

The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

We are delighted to inform you that the survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology. The report also included assessment of homologous recombination deficiency (HRD) as a potential prognostic and predictive factor in triple-negative breast cancer.

Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response - final results from GeparSixto. Ann Oncol. 2018 Oct 18 [Epub ahead of print]

In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC) (von Minckwitz et al. Lancet Oncol 2014). TNBC is frequently associated with germline mutations of the BRCA1/2 genes which are critical for repairing DNA double-strand breaks. Homologous recombination deficiency (HRD) of DNA repair is a common feature in BRCA-related tumors and can be consider as a possible DNA repair–targeted treatment approach.
In this study, we showed that carboplatin as part of a neoadjuvant anthracycline/taxane-based chemotherapy statistically significantly improves disease-free survival (DFS; HR=0.56, [95%CI 0.34-0.93]; p=0.022), with a strong trend towards a better overall survival (OS; HR=0.60 [95%CI 0.32-1.12; p=0.106) in TNBC, whereas no significant difference was observed for both DFS and OS in HER2-positive tumors. Hence, these findings support the neoadjuvant use of carboplatin in TNBC. Additionally, in patients with TNBC the HRD was predictor of response but did not predict the effect of carboplatin.


News

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd